Literature DB >> 27506748

Functional and proteomic alterations of plasma high density lipoproteins in type 1 diabetes mellitus.

Shankarappa Manjunatha1, Klaus Distelmaier1, Surendra Dasari2, Rickey E Carter2, Yogish C Kudva1, K Sreekumaran Nair3.   

Abstract

OBJECTIVE: Higher HDL-cholesterol (HDL-C) is linked to lower cardiovascular risk but individuals with type 1 diabetes mellitus (T1DM) with normal or high HDL-C have higher cardiovascular events compared to age matched non-diabetic controls (ND). We determined whether altered HDL functions despite having normal HDL-C concentration may explain increased cardiovascular risk in T1DM individuals. We also determined whether irreversible posttranslational modifications (PTMs) of HDL bound proteins occur in T1DM individuals with altered HDL functions.
METHODS: T1DM with poor glycemic control (T1D-PC, HbA1c≥8.5%, n=15) and T1DM with good glycemic control (T1D-GC, HbA1c≤6.6%, n=15) were compared with equal numbers of NDs, ND-PC and ND-GC respectively, matched for age, sex and body mass index (BMI). We measured cholesterol efflux capacity (CEC) of HDL in the serum using J774 macrophages, antioxidant function of HDL as the ability to reverse the oxidative damage of LDL and PON1 activity using commercially available kit. For proteomic analysis, HDL was isolated by density gradient ultracentrifugation and was analyzed by mass spectrometry and shotgun proteomics method.
RESULTS: Plasma HDL-C concentrations in both T1DM groups were similar to their ND. However, CEC (%) of T1D-PC (16.9±0.8) and T1D-GC (17.1±1) were lower than their respective ND (17.9±1, p=0.01 and 18.2±1.4, p=0.02). HDL antioxidative function also was lower (p<0.05). The abundance of oxidative PTMs of apolipoproteins involved in CEC and antioxidative functions of HDL were higher in T1D-PC (ApoA4, p=0.041) and T1D-GC (ApoA4, p=0.025 and ApoE, p=0.041) in comparison with ND. Both T1D-PC and T1D-GC groups had higher abundance of amadori modification of ApoD (p=0.002 and p=0.041 respectively) and deamidation modification of ApoA4 was higher in T1D-PC (p=0.025).
CONCLUSIONS: Compromised functions of HDL particles in T1DM individuals, irrespective of glycemic control, could be explained by higher abundance of irreversible PTMs of HDL proteins. These results lend mechanistic support to the hypothesis that HDL quality rather than quantity determines HDL function in T1DM and suggest that measurements of concentrations of HbA1c and HDL-C are not sufficient as biomarkers of effective treatment to lower cardiovascular risk in T1DM individuals.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Functions; High density lipoproteins; Posttranslational modifications; Proteomics; Type 1 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 27506748     DOI: 10.1016/j.metabol.2016.06.008

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  19 in total

Review 1.  Insulin Regulation of Proteostasis and Clinical Implications.

Authors:  Haleigh A James; Brian T O'Neill; K Sreekumaran Nair
Journal:  Cell Metab       Date:  2017-07-14       Impact factor: 27.287

Review 2.  Unbiased and targeted mass spectrometry for the HDL proteome.

Authors:  Sasha A Singh; Masanori Aikawa
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

Review 3.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

4.  Glycation of HDL blunts its anti-inflammatory and cholesterol efflux capacities in vitro, but has no effect in poorly controlled type 1 diabetes subjects.

Authors:  Diego Gomes Kjerulf; Shari Wang; Mohamed Omer; Asha Pathak; Savitha Subramanian; Chang Yeop Han; Chongren Tang; Laura J den Hartigh; Baohai Shao; Alan Chait
Journal:  J Diabetes Complications       Date:  2020-07-31       Impact factor: 2.852

5.  High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes.

Authors:  Tomas Vaisar; Jenny E Kanter; Jake Wimberger; Angela D Irwin; John Gauthier; Emily Wolfson; Vanessa Bahnam; I-Hsien Wu; Hetal Shah; Hillary A Keenan; Carla J Greenbaum; George L King; Jay W Heinecke; Karin E Bornfeldt
Journal:  Diabetes Care       Date:  2019-10-09       Impact factor: 19.112

Review 6.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

7.  Glycation Reduces the Stability of ApoAI and Increases HDL Dysfunction in Diet-Controlled Type 2 Diabetes.

Authors:  Sangeeta R Kashyap; Abdullah Osme; Serguei Ilchenko; Makan Golizeh; Kwangwon Lee; Shuhui Wang; James Bena; Stephen F Previs; Jonathan D Smith; Takhar Kasumov
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

8.  HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: a cross-sectional study.

Authors:  Mohamad O Ahmed; Rachel E Byrne; Agnieszka Pazderska; Ricardo Segurado; Weili Guo; Anjuli Gunness; Isolda Frizelle; Mark Sherlock; Khalid S Ahmed; Anne McGowan; Kevin Moore; Gerard Boran; Fiona C McGillicuddy; James Gibney
Journal:  Diabetologia       Date:  2020-11-09       Impact factor: 10.122

9.  Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.

Authors:  Liliana Fonseca; Sílvia Paredes; Helena Ramos; José Carlos Oliveira; Isabel Palma
Journal:  Lipids Health Dis       Date:  2020-06-06       Impact factor: 3.876

10.  Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study.

Authors:  Evgenia Gourgari; Martin P Playford; Umberto Campia; Amit K Dey; Fran Cogen; Stephanie Gubb-Weiser; Mihriye Mete; Sameer Desale; Maureen Sampson; Allen Taylor; Kristina I Rother; Alan T Remaley; Nehal N Mehta
Journal:  Cardiovasc Diabetol       Date:  2018-12-19       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.